{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:08:30Z","timestamp":1788246510370,"version":"build-2803163510"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Herpes Zoster (HZ) is a viral skin disease caused by reactivation of latent Varicella Zoster Virus (VZV) in human ganglia, presenting with unilateral neuropathic pain and vesicular rash. HZ imposes significant burden on patients and healthcare systems, often complicated by postherpetic neuralgia (PHN). The live attenuated zoster vaccine (ZVL, Zostavax) reduces HZ risk by 51% and PHN by 65% in adults \u226560\u202fyears. The recombinant zoster vaccine (RZV, Shingrix) shows approximately 90% efficacy in adults \u226550\u202fyears. Despite withdrawal of Zostavax from the U.S. market, RZV uptake remains suboptimal due to vaccine hesitancy and provider knowledge gaps. This study aims to analyze global research trends on HZ vaccines using bibliometric methods.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Publications on \u201cherpes zoster\u201d and \u201czoster vaccine\u201d were retrieved from the Web of Science Core Collection (WoSCC) database (1999\u20132024). Bibliometric and visualization tools including CiteSpace, VOSviewer, and R-bibliometrix were applied to analyze contributions by countries, institutions, journals, authors, references, and keywords.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 719 articles from 261 journals across 56 countries were included. The United States led publications, with GlaxoSmithKline (GSK) as the most prolific institution. <jats:italic>Vaccine<\/jats:italic> was the most prolific journal; Levin et al. was the most productive author. The most cited article, \u201cEfficacy of the Herpes Zoster Subunit Vaccine in Adults Aged 70\u202fYears or Older,\u201d by Cunningham AL, appeared in the <jats:italic>New England Journal of Medicine<\/jats:italic>. Frequently used keywords included \u201cherpes zoster,\u201d \u201cvaccination,\u201d \u201cpostherpetic neuralgia,\u201d \u201cefficacy,\u201d \u201csubunit vaccine,\u201d and \u201csafety\u201d.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This bibliometric study comprehensively summarizes HZ vaccine research over 25\u202fyears, offering insights to guide future research and clinical practice.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1516450","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T05:27:55Z","timestamp":1752125275000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Bibliometric analysis and visualization mapping of herpes zoster vaccine publications from 1999 to 2024"],"prefix":"10.3389","volume":"12","author":[{"given":"Wenli","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.nurpra.2019.10.013","article-title":"Shingles: not just a rash","volume":"16","author":"Carter","year":"2020","journal-title":"J Nurse Pract"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1212\/WNL.0b013e3182a3516e","article-title":"The global epidemiology of herpes zoster","volume":"81","author":"Yawn","year":"2013","journal-title":"Neurology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12879-015-0810-6","article-title":"The epidemiology of herpes zoster and its complications in Medicare cancer patients","volume":"15","author":"Yenikomshian","year":"2015","journal-title":"BMC Infect Dis"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1093\/cid\/ciu1161","article-title":"Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHdh-Anrs co4 cohort","volume":"60","author":"Grabar","year":"2015","journal-title":"Clin Infect Dis"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"S127","DOI":"10.1093\/infdis\/jiy382","article-title":"Herpes Zoster Vaccines","volume":"218","author":"Cunningham","year":"2018","journal-title":"J Infect Dis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1016\/j.vaccine.2018.05.078","article-title":"Live zoster vaccination in an immunocompromised patient leading to death secondary to disseminated varicella zoster virus infection","volume":"36","author":"Alexander","year":"2018","journal-title":"Vaccine"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00842","article-title":"Knowledge mapping of drug-induced liver injury: a Scientometric investigation (2010-2019)","volume":"11","author":"Ke","year":"2020","journal-title":"Front Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.datak.2008.05.004","article-title":"The thematic and citation landscape of data and knowledge engineering (1985-2007)","volume":"67","author":"Chen","year":"2008","journal-title":"Data Knowl Eng"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/asi.20317","article-title":"CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature","volume":"57","author":"Chen","year":"2006","journal-title":"J Am Soc Inf Sci Technol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","article-title":"Software survey: Vosviewer, a computer program for bibliometric mapping","volume":"84","author":"Van Eck","year":"2010","journal-title":"Scientometrics"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"850762","DOI":"10.3389\/fmed.2022.850762","article-title":"Research trends and hotspots on herpes zoster: a 10-year bibliometric analysis (2012-2021)","volume":"9","author":"Zhang","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.2147\/JPR.S409616","article-title":"Top 100 Most-cited papers in herpes zoster from 2000 to 2022: a bibliometric study","volume":"16","author":"Gao","year":"2023","journal-title":"J Pain Res"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.2147\/JPR.S432485","article-title":"Comprehensive bibliometric analysis of research articles on post-herpetic neuralgia and varicella-zoster virus: a 20-year review (2003-2022)","volume":"16","author":"Zhang","year":"2023","journal-title":"J Pain Res"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an Adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","article-title":"Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older","volume":"217","author":"Cunningham","year":"2018","journal-title":"J Infect Dis"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1093\/cid\/ciab629","article-title":"The Adjuvanted recombinant zoster vaccine confers long-term protection against herpes zoster: interim results of an extension study of the pivotal phase 3 clinical trials Zoe-50 and Zoe-70","volume":"74","author":"Boutry","year":"2022","journal-title":"Clin Infect Dis"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.15585\/mmwr.mm7103a2","article-title":"Use of recombinant zoster vaccine in immunocompromised adults aged \u226519 years: recommendations of the advisory committee on immunization practices\u2014United States, 2022","volume":"71","author":"Anderson","year":"2022","journal-title":"MMWR-Morb Mortal Wkly Rep"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1002\/cncr.31909","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: a randomized trial","volume":"125","author":"Vink","year":"2019","journal-title":"Cancer"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1740774513512185","article-title":"Use of health plan combined with registry data to predict clinical trial recruitment","volume":"11","author":"Curtis","year":"2014","journal-title":"Clin Trials"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3390\/ijms24086967","article-title":"Immunogenicity and Safety of Adjuvanted Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients on Anti-Cellular Biologic Agents or JAK Inhibitors: A Prospective Observational Study","volume":"24","author":"Venerito","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1007\/s12325-016-0355-0","article-title":"Real-world effectiveness and safety of a live-attenuated herpes zoster vaccine: a comprehensive review","volume":"33","author":"Ansaldi","year":"2016","journal-title":"Adv Ther"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e0313889","DOI":"10.1371\/journal.pone.0313889","article-title":"Systematic review and meta-analysis of recombinant herpes zoster vaccine in immunocompromised populations","volume":"19","author":"Marra","year":"2024","journal-title":"PLoS One"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2217\/fvl-2022-0028","article-title":"Evidence-based policies in public health to address Covid-19 vaccine hesitancy","volume":"18","author":"Chirico","year":"2023","journal-title":"Future Virol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"100299","DOI":"10.1016\/j.jvacx.2023.100299","article-title":"Trust and vaccine hesitancy during the Covid-19 pandemic: a cross-national analysis","volume":"14","author":"Jennings","year":"2023","journal-title":"Vaccine X"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1001\/jama.295.1.90","article-title":"The history and meaning of the journal impact factor","volume":"295","author":"Garfield","year":"2006","journal-title":"JAMA"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"25151355221084535","DOI":"10.1177\/25151355221084535","article-title":"Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review","volume":"10","author":"Pan","year":"2022","journal-title":"Ther Adv Vaccines Immunother"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"S429","DOI":"10.1093\/infdis\/jiab387","article-title":"Herpes zoster vaccines","volume":"224","author":"Harbecke","year":"2021","journal-title":"J Infect Dis"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jinf.2013.04.010","article-title":"Safety, humoral and cell-mediated immune responses to herpes zoster vaccine in subjects with diabetes mellitus","volume":"67","author":"Hata","year":"2013","journal-title":"J Infect"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/ofid\/ofad137","article-title":"Increased myocardial infarction risk following herpes zoster infection","volume":"10","author":"Parameswaran","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1371\/journal.pone.0228409","article-title":"Higher risk of herpes zoster in stroke patients","volume":"15","author":"Tung","year":"2020","journal-title":"PLoS One"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12889-023-16768-4","article-title":"The association of herpes zoster and influenza vaccinations with the risk of developing dementia: a population-based cohort study within the UK clinical practice research datalink","volume":"23","author":"Lophatananon","year":"2023","journal-title":"BMC Public Health"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"e3415","DOI":"10.1002\/brb3.3415","article-title":"Herpes zoster vaccination and the risk of dementia: a systematic review and meta-analysis","volume":"14","author":"Shah","year":"2024","journal-title":"Brain Behav"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/j.cgh.2006.09.019","article-title":"Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease","volume":"4","author":"Gupta","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1093\/ecco-jcc\/jjac040","article-title":"Safety of recombinant zoster vaccine in patients with inflammatory bowel disease","volume":"16","author":"Khan","year":"2022","journal-title":"J Crohns Colitis"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.3899\/jrheum.130170","article-title":"Herpes zoster vaccination in Sle: a pilot study of immunogenicity","volume":"40","author":"Guthridge","year":"2013","journal-title":"J Rheumatol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1136\/annrheumdis-2019-215925","article-title":"Safety and immune response of a live-attenuated herpes zoster vaccine in patients with systemic lupus erythematosus: a randomised placebo-controlled trial","volume":"78","author":"Mok","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"R174","DOI":"10.1186\/ar3497","article-title":"The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study","volume":"13","author":"Zhang","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jbspin.2016.04.001","article-title":"Herpes zoster: risk and prevention during immunomodulating therapy","volume":"84","author":"Tran","year":"2017","journal-title":"Joint Bone Spine"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"894","DOI":"10.4161\/hv.6.11.12852","article-title":"Concomitant administration of zoster and pneumococcal vaccines in adults \u226560 years old","volume":"6","author":"Macintyre","year":"2010","journal-title":"Hum Vaccines"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.vaccine.2017.08.029","article-title":"Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine","volume":"36","author":"Levin","year":"2018","journal-title":"Vaccine"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jinf.2021.12.033","article-title":"The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged \u226550 years: a randomized trial","volume":"84","author":"Min","year":"2022","journal-title":"J Infect"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1016\/j.vaccine.2018.05.110","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults \u226550 years of age: a randomized trial","volume":"36","author":"Mar\u00e9chal","year":"2018","journal-title":"Vaccine"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/ofid\/ofac011","article-title":"Herpes zoster following recombinant zoster vaccine with or without concomitant vaccination","volume":"9","author":"Bruxvoort","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1080\/21645515.2017.1345399","article-title":"Assessment of the potential public health impact of herpes zoster vaccination in Germany","volume":"13","author":"Curran","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1080\/21645515.2019.1657753","article-title":"The potential public health impact of herpes zoster vaccination in the 65 years of age cohort in Italy","volume":"16","author":"Volpi","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s40121-022-00749-y","article-title":"Reduction in herpes zoster antiviral use since the introduction of the live-attenuated zoster vaccine on Australia's National Immunisation Program: a population-based study from 1994 to 2019","volume":"12","author":"Phakey","year":"2023","journal-title":"Infect Dis Ther"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"e025553","DOI":"10.1136\/bmjopen-2018-025553","article-title":"Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the Uk universal mass vaccination programme","volume":"9","author":"Van Oorschot","year":"2019","journal-title":"BMJ Open"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1093\/infdis\/jix482","article-title":"Immunogenicity and safety of the Hz\/su Adjuvanted herpes zoster subunit vaccine in adults previously vaccinated with a live attenuated herpes zoster vaccine","volume":"216","author":"Grupping","year":"2017","journal-title":"J Infect Dis"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1136\/bmj-2023-076321","article-title":"Effectiveness of the live zoster vaccine during the 10 years following vaccination: real world cohort study using electronic health records","volume":"383","author":"Klein","year":"2023","journal-title":"BMJ British Med J"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/aje\/kwx245","article-title":"Long-term effectiveness of the live zoster vaccine in preventing shingles: a cohort study","volume":"187","author":"Baxter","year":"2018","journal-title":"Am J Epidemiol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/vaccines10040529","article-title":"Enhanced potency and persistence of immunity to varicella-zoster virus glycoprotein E in mice by addition of a novel Bc02 compound adjuvant","volume":"10","author":"Li","year":"2022","journal-title":"Vaccine"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"973","DOI":"10.3390\/pharmaceutics14050973","article-title":"Ionizable lipid nanoparticles enhanced the synergistic adjuvant effect of CpG ODNs and QS21 in a varicella zoster virus glycoprotein E subunit vaccine","volume":"14","author":"Luan","year":"2022","journal-title":"Pharmaceutics"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"e2310886","DOI":"10.1002\/adma.202310886","article-title":"A synergistic lipid nanoparticle encapsulating mRNA shingles vaccine induces potent immune responses and protects Guinea pigs from viral challenges","volume":"36","author":"Cheng","year":"2024","journal-title":"Adv Mater"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.3390\/v15122288","article-title":"Immunogenicity in mice immunized with recombinant adenoviruses expressing varicella-zoster virus envelope glycoprotein E","volume":"15","author":"Zheng","year":"2023","journal-title":"Viruses Basel"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"5891","DOI":"10.1016\/j.vaccine.2020.07.004","article-title":"Acceptability and perception of the herpes zoster vaccine in the 65 and over population: a French observational study","volume":"38","author":"Del Signore","year":"2020","journal-title":"Vaccine"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12879-024-09344-7","article-title":"Herpes zoster (Hz) vaccine coverage and confidence in Italy: a Nationwide cross-sectional study, the Obvious project","volume":"24","author":"Salussolia","year":"2024","journal-title":"BMC Infect Dis"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/j.vaccine.2019.11.065","article-title":"Knowledge about vaccines and vaccination in older people: results of a national survey by the Italian Society for Gerontology & geriatrics","volume":"38","author":"Ecarnot","year":"2020","journal-title":"Vaccine"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/ICO.0000000000000503","article-title":"Management and prevention of herpes zoster ocular disease","volume":"34","author":"Cohen","year":"2015","journal-title":"Cornea"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12121441","article-title":"Challenges and opportunities for adult vaccine coverage: insights for healthcare professionals focusing on herpes zoster in Mexico","volume":"12","author":"Cervantes-Apolinar","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"4191","DOI":"10.1016\/j.vaccine.2015.04.041","article-title":"Strategies intended to address vaccine hesitancy: review of published reviews","volume":"33","author":"Dub\u00e9","year":"2015","journal-title":"Vaccine"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.ebiom.2016.08.042","article-title":"The state of vaccine confidence 2016: global insights through a 67-country survey","volume":"12","author":"Larson","year":"2016","journal-title":"EBioMedicine"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1136\/bmj.326.7400.1167","article-title":"Pharmaceutical industry sponsorship and research outcome and quality: systematic review","volume":"326","author":"Lexchin","year":"2003","journal-title":"BMJ"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1001\/jama.289.4.454","article-title":"Scope and impact of financial conflicts of interest in biomedical research: a systematic review","volume":"289","author":"Bekelman","year":"2003","journal-title":"JAMA"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/S0140-6736(14)61646-9","article-title":"Health-system reform and universal health coverage in Latin America","volume":"385","author":"Atun","year":"2015","journal-title":"Lancet"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/S0140-6736(97)02419-7","article-title":"Language bias in randomised controlled trials published in English and German","volume":"350","author":"Egger","year":"1997","journal-title":"Lancet"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0895-4356(94)00098-B","article-title":"Selecting the language of the publications included in a meta-analysis: is there a tower of babel bias?","volume":"48","author":"Gr\u00e9goire","year":"1995","journal-title":"J Clin Epidemiol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1516450\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T05:27:56Z","timestamp":1752125276000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1516450\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":68,"alternative-id":["10.3389\/fmed.2025.1516450"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1516450","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"article-number":"1516450"}}